Form 8-K

8-K — THERMO FISHER SCIENTIFIC INC.

Accession: 0000097745-26-000086

Filed: 2026-04-23

Period: 2026-04-23

CIK: 0000097745

SIC: 3829 (MEASURING & CONTROLLING DEVICES, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tmo-20260423.htm (Primary)

EX-99.1 (q12026earnings8kex99_1.htm)

GRAPHIC (image_0a.jpg)

GRAPHIC (image_1a.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: tmo-20260423.htm · Sequence: 1

tmo-20260423

0000097745FALSE00000977452026-04-232026-04-230000097745us-gaap:CommonStockMember2026-04-232026-04-230000097745tmo:A1.45SeniorNotesDue2027Member2026-04-232026-04-230000097745tmo:SeniorNotes175Due2027Member2026-04-232026-04-230000097745tmo:FloatingSeniorRateNotesDue2027Member2026-04-232026-04-230000097745tmo:SeniorNotes0.500Due2028Member2026-04-232026-04-230000097745tmo:SeniorNotes1.375Due2028Member2026-04-232026-04-230000097745tmo:SeniorNotes1.95Due2029Member2026-04-232026-04-230000097745tmo:SeniorNotes0.875Due2031Member2026-04-232026-04-230000097745tmo:SeniorNotes2375Due2032Member2026-04-232026-04-230000097745tmo:SeniorNotes3650Due2034Member2026-04-232026-04-230000097745tmo:SeniorNotes3.628Due2035Member2026-04-232026-04-230000097745tmo:SeniorNotes2.875Due2037Member2026-04-232026-04-230000097745tmo:SeniorNotes1.500Due2039Member2026-04-232026-04-230000097745tmo:SeniorNotes1.875Due2049Member2026-04-232026-04-23

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2026

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its Charter)

Delaware 1-8002 04-2209186

(State of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

168 Third Avenue

Waltham, Massachusetts 02451

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $1.00 par value TMO New York Stock Exchange

1.450% Notes due 2027 TMO 27 New York Stock Exchange

1.750% Notes due 2027 TMO 27B New York Stock Exchange

Floating Rate Notes due 2027 TMO 27D New York Stock Exchange

0.500% Notes due 2028 TMO 28A New York Stock Exchange

1.375% Notes due 2028 TMO 28 New York Stock Exchange

1.950% Notes due 2029 TMO 29 New York Stock Exchange

0.875% Notes due 2031 TMO 31 New York Stock Exchange

2.375% Notes due 2032 TMO 32 New York Stock Exchange

3.650% Notes due 2034 TMO 34 New York Stock Exchange

3.628% Notes due 2035 TMO 35A New York Stock Exchange

2.875% Notes due 2037 TMO 37 New York Stock Exchange

1.500% Notes due 2039 TMO 39 New York Stock Exchange

1.875% Notes due 2049 TMO 49 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 23, 2026, the Registrant announced its financial results for the fiscal quarter ended March 28, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated April 23, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERMO FISHER SCIENTIFIC INC.

Date: April 23, 2026 By: /s/ Joseph R. Holmes

Joseph R. Holmes

Vice President and Chief Accounting Officer

EX-99.1

Filename: q12026earnings8kex99_1.htm · Sequence: 2

Document

Exhibit 99.1

News

Media Contact Information:

Sandy Pound

Thermo Fisher Scientific

Investor Contact Information:

Rafael Tejada

Thermo Fisher Scientific

Phone: 781-622-1223

Phone: 781-622-1356

E-mail: sandy.pound@thermofisher.com

E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Reports First Quarter 2026 Results

WALTHAM, Mass. (April 23, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

First Quarter Highlights

•First quarter revenue grew 6% to $11.01 billion.

•First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43.

•First quarter adjusted EPS grew 6% to $5.44.

•Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company.

•Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included the Thermo Scientific™ Glacios™ 3 Cryo-TEM, a next-generation cryo-transmission electron microscope designed to enable installation in a broader range of lab spaces, democratizing access to cryo-EM for use in structural biology; the Thermo Scientific™ TSQ Certis™ triple quadrupole mass spectrometer, which enhances productivity and reliability by delivering faster, high-quality results to support analytical testing across pharmaceutical and applied laboratories; the Thermo Scientific™ Niton™ XL5e Handheld XRF Analyzer, which enables industrial and applied customers to improve the speed and accuracy of identifying materials in the field; and the Gibco™ CTS™ Compleo™ Fill and Finish System, which increases productivity and reliability in cell therapy manufacturing, supporting scalable production of advanced therapies.

•Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers. During the quarter, we announced a strategic collaboration with NVIDIA, combining our leadership in laboratory technologies with NVIDIA’s AI capabilities to advance scientific instrumentation, improve laboratory performance and accelerate scientific breakthroughs. We also announced a strategic collaboration with SHL Medical to deliver fully integrated sterile fill-finish and device assembly solutions, advancing our U.S. drug product manufacturing capabilities and helping pharma and biotech customers accelerate development and commercialization of important medicines.

•Continued to successfully execute our capital deployment strategy. During the quarter, we completed the acquisition of Clario, an industry-leading provider of endpoint data solutions, repurchased $3.0 billion of stock and increased our dividend by 10%.

“We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational excellence and enable our customers’ success,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “We continued to make great progress executing our strategy, further strengthening our capabilities with the addition of Clario.”

Casper added, “Looking ahead, we are well positioned to deliver a strong year. As the trusted partner to our customers, we are uniquely equipped to help them accelerate their innovation and enhance their productivity. Through our global scale and the power of the PPI Business System, we will continue to actively manage the company to create value for our stakeholders and build an even brighter future for our company."

First Quarter 2026

Revenue for the first quarter of 2026 grew 6% to $11.01 billion, versus $10.36 billion in the same quarter of 2025. Organic revenue growth was 1%.

GAAP Earnings Results

GAAP diluted EPS in the first quarter of 2026 was $4.43, 11% growth versus the first quarter of 2025. GAAP operating income for the first quarter of 2026 was $1.86 billion, 9% higher than the year-ago quarter. GAAP operating margin was 16.9%, compared with 16.6% in the first quarter of 2025.

Non-GAAP Earnings Results

Adjusted EPS for the first quarter of 2026 was $5.44, 6% growth versus the first quarter of 2025. Adjusted operating income for the first quarter of 2026 was $2.40 billion, 6% higher than the year-ago quarter. Adjusted operating margin was 21.8%, compared with 21.9% in the first quarter of 2025.

Annual Guidance for 2026

The company will provide updated 2026 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.

Use of Non-GAAP Financial Measures

Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, and organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.

Note on Presentation

Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Conference Call

Thermo Fisher Scientific will hold its earnings conference call today, April 23, 2026, at 8:30 a.m. Eastern Time. During the call, the company will discuss its financial performance, as well as future expectations.

The call will be webcast live on the “Investors” section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 723173.

The earnings press release and related information can also be found on the Investor Relations section of our website, under the heading “Financials”. A replay of the call will be available under “News, Events & Presentations” through Wednesday, July 22, 2026.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent reports on Form 10-K and Form 10-Q under the heading “Risk Factors.” These

filings are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” These forward-looking statements are based on our current expectations and speak only as of the date of this press release. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, in the event of new information, future developments or otherwise.

###

Condensed Consolidated Statements of Income (unaudited)

Three months ended

March 28, % of March 29, % of

(Dollars in millions except per share amounts) 2026 Revenues 2025 Revenues

Revenues $ 11,005 $ 10,364

Costs and operating expenses:

Cost of revenues (a) 6,529 59.3 % 6,056 58.4 %

Selling, general and administrative expenses (b) 1,798 16.3 % 1,721 16.6 %

Amortization of acquisition-related intangible assets 430 3.9 % 429 4.1 %

Research and development expenses 336 3.1 % 342 3.3 %

Restructuring and other costs (c) 49 0.4 % 98 1.0 %

Total costs and operating expenses 9,142 83.1 % 8,648 83.4 %

Operating income 1,863 16.9 % 1,716 16.6 %

Interest income 233 203

Interest expense (354) (303)

Other income/(expense) (d) (9) 3

Income before income taxes 1,734 1,620

Benefit from/(provision for) income taxes (e) (70) (95)

Equity in earnings/(losses) of unconsolidated entities (8) (14)

Net income 1,656 1,511

Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest 5 4

Net income attributable to Thermo Fisher Scientific Inc. $ 1,651 15.0 % $ 1,507 14.5 %

Earnings per share attributable to Thermo Fisher Scientific Inc.:

Basic $ 4.44 $ 3.99

Diluted $ 4.43 $ 3.98

Weighted average shares:

Basic 372 378

Diluted 373 379

Reconciliation of adjusted operating income and adjusted operating margin

GAAP operating income $ 1,863 16.9 % $ 1,716 16.6 %

Cost of revenues adjustments (a) 14 0.1 % 11 0.1 %

Selling, general and administrative expenses adjustments (b) 43 0.4 % 14 0.1 %

Restructuring and other costs (c) 49 0.4 % 98 1.0 %

Amortization of acquisition-related intangible assets 430 3.9 % 429 4.1 %

Adjusted operating income (non-GAAP measure) $ 2,399 21.8 % $ 2,269 21.9 %

Reconciliation of adjusted net income

GAAP net income attributable to Thermo Fisher Scientific Inc.

$ 1,651 $ 1,507

Cost of revenues adjustments (a) 14 11

Selling, general and administrative expenses adjustments (b) 43 14

Restructuring and other costs (c) 49 98

Amortization of acquisition-related intangible assets 430 429

Other income/expense adjustments (d) 1 (1)

Income taxes adjustments (e) (168) (122)

Equity in earnings/losses of unconsolidated entities 8 14

Adjusted net income (non-GAAP measure)

$ 2,027 $ 1,950

Reconciliation of adjusted earnings per share

GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. $ 4.43 $ 3.98

Cost of revenues adjustments (a) 0.04 0.03

Selling, general and administrative expenses adjustments (b) 0.12 0.04

Restructuring and other costs (c) 0.13 0.26

Amortization of acquisition-related intangible assets 1.15 1.13

Other income/expense adjustments (d) 0.00 0.00

Income taxes adjustments (e) (0.45) (0.32)

Equity in earnings/losses of unconsolidated entities 0.02 0.04

Adjusted EPS (non-GAAP measure) $ 5.44 $ 5.15

Reconciliation of free cash flow

GAAP net cash provided by operating activities

$ 1,192 $ 723

Purchases of property, plant and equipment

(376) (362)

Proceeds from sale of property, plant and equipment 9 12

Free cash flow (non-GAAP measure) $ 825 $ 373

Business Segment Information Three months ended

March 28, % of March 29, % of

(Dollars in millions) 2026 Revenues 2025 Revenues

Revenues

Life Sciences Solutions $ 2,636 23.9 % $ 2,341 22.6 %

Analytical Instruments 1,716 15.6 % 1,718 16.6 %

Specialty Diagnostics 1,142 10.4 % 1,148 11.1 %

Laboratory Products and Biopharma Services

6,036 54.8 % 5,640 54.4 %

Eliminations (524) -4.8 % (482) -4.7 %

Consolidated revenues $ 11,005 100.0 % $ 10,364 100.0 %

Segment income and segment income margin

Life Sciences Solutions $ 954 36.2 % $ 834 35.6 %

Analytical Instruments 355 20.7 % 399 23.2 %

Specialty Diagnostics 313 27.4 % 304 26.5 %

Laboratory Products and Biopharma Services 778 12.9 % 731 13.0 %

Subtotal reportable segments 2,399 21.8 % 2,269 21.9 %

Cost of revenues adjustments (a) (14) -0.1 % (11) -0.1 %

Selling, general and administrative expenses adjustments (b) (43) -0.4 % (14) -0.1 %

Restructuring and other costs (c) (49) -0.4 % (98) -1.0 %

Amortization of acquisition-related intangible assets (430) -3.9 % (429) -4.1 %

Consolidated GAAP operating income $ 1,863 16.9 % $ 1,716 16.6 %

(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges/(credits) for the sale of inventory revalued at the date of acquisition. Adjusted results in 2026 also exclude $3 of transaction-related costs.

(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, and charges/credits for changes in estimates of contingent acquisition consideration. Adjusted results in 2026 also exclude $2 of accelerated depreciation on fixed assets to be abandoned due to facility consolidations.

(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.

(d) Adjusted results exclude net gains/losses on investments.

(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements.

Note:

Consolidated depreciation expense is $306 and $276 in 2026 and 2025, respectively.

Organic revenue growth Three months ended

March 28, 2026

Revenue growth 6 %

Acquisitions 3 %

Currency translation 2 %

Organic revenue growth (non-GAAP measure) 1 %

Note:

For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.

Condensed Consolidated Balance Sheets (unaudited)

March 28, December 31,

(In millions) 2026 2025

Assets

Current assets:

Cash and cash equivalents $ 3,254 $ 9,852

Short-term investments 2 253

Accounts receivable, net 9,204 8,900

Inventories 5,496 5,425

Other current assets 4,361 4,278

Total current assets

22,316 28,707

Property, plant and equipment, net 10,658 10,565

Acquisition-related intangible assets, net 19,146 15,838

Other assets

5,973 5,871

Goodwill 55,187 49,362

Total assets

$ 113,281 $ 110,343

Liabilities, redeemable noncontrolling interest and equity

Current liabilities:

Short-term obligations and current maturities of long-term obligations

$ 3,090 $ 3,533

Other current liabilities 11,531 11,656

Total current liabilities

14,621 15,189

Other long-term liabilities 6,527 5,766

Long-term obligations

40,071 35,852

Redeemable noncontrolling interest 121 122

Total equity 51,940 53,415

Total liabilities, redeemable noncontrolling interest and equity $ 113,281 $ 110,343

Condensed Consolidated Statements of Cash Flows (unaudited)

Three months ended

March 28, March 29,

(In millions) 2026 2025

Operating activities

Net income $ 1,656 $ 1,511

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 736 706

Change in deferred income taxes (258) (279)

Other non-cash expenses, net 171 210

Changes in assets and liabilities, excluding the effects of acquisitions (1,112) (1,425)

Net cash provided by operating activities 1,192 723

Investing activities

Purchases of property, plant and equipment (376) (362)

Proceeds from sale of property, plant and equipment 9 12

Proceeds from cross-currency interest rate swap interest settlements 96 87

Acquisitions, net of cash acquired (8,872) —

Purchases of investments (14) (264)

Proceeds from sales and maturities of investments 250 2

Other investing activities, net (55) (1)

Net cash used in investing activities (8,961) (527)

Financing activities

Net proceeds from issuance of debt 5,238 2,840

Repayment of debt (1,412) (838)

Proceeds from issuance of commercial paper 389 —

Purchases of company common stock (3,000) (2,000)

Dividends paid (162) (149)

Other financing activities, net 39 45

Net cash provided by (used in) financing activities 1,093 (102)

Exchange rate effect on cash 78 37

Increase/(decrease) in cash, cash equivalents and restricted cash (6,599) 132

Cash, cash equivalents and restricted cash at beginning of period 9,879 4,040

Cash, cash equivalents and restricted cash at end of period $ 3,280 $ 4,172

Free cash flow (non-GAAP measure) $ 825 $ 373

Note:

For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.

Supplemental Information Regarding Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions/divestitures and the effects of currency translation. We report these measures because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures, and/or foreign currency translation on revenues. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

•Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.

•Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs.

•Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

•The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

•The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions, transaction-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.

The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.

GRAPHIC

Filename: image_0a.jpg · Sequence: 7

Binary file (3783 bytes)

Download image_0a.jpg

GRAPHIC

Filename: image_1a.jpg · Sequence: 8

Binary file (63949 bytes)

Download image_1a.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 10

v3.26.1

Document and Entity Information

Apr. 23, 2026

Entity Listings [Line Items]

Document Type

8-K

Document Period End Date

Apr. 23, 2026

Entity Registrant Name

THERMO FISHER SCIENTIFIC INC.

Entity Incorporation, State or Country Code

Entity File Number

1-8002

Entity Tax Identification Number

04-2209186

Entity Address, Address Line One

168 Third Avenue

Entity Address, City or Town

Waltham

Entity Address, State or Province

Entity Address, Postal Zip Code

02451

City Area Code

781

Local Phone Number

622-1000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0000097745

Amendment Flag

false

Common Stock, $1.00 par value

Entity Listings [Line Items]

Title of 12(b) Security

Common Stock, $1.00 par value

Trading Symbol

TMO

Security Exchange Name

NYSE

1.450% Notes due 2027

Entity Listings [Line Items]

Title of 12(b) Security

1.450% Notes due 2027

Trading Symbol

TMO 27

Security Exchange Name

NYSE

1.750% Notes due 2027

Entity Listings [Line Items]

Title of 12(b) Security

1.750% Notes due 2027

Trading Symbol

TMO 27B

Security Exchange Name

NYSE

Floating Rate Notes due 2027

Entity Listings [Line Items]

Title of 12(b) Security

Floating Rate Notes due 2027

Trading Symbol

TMO 27D

Security Exchange Name

NYSE

0.500% Notes due 2028

Entity Listings [Line Items]

Title of 12(b) Security

0.500% Notes due 2028

Trading Symbol

TMO 28A

Security Exchange Name

NYSE

1.375% Notes due 2028

Entity Listings [Line Items]

Title of 12(b) Security

1.375% Notes due 2028

Trading Symbol

TMO 28

Security Exchange Name

NYSE

1.950% Notes due 2029

Entity Listings [Line Items]

Title of 12(b) Security

1.950% Notes due 2029

Trading Symbol

TMO 29

Security Exchange Name

NYSE

0.875% Notes due 2031

Entity Listings [Line Items]

Title of 12(b) Security

0.875% Notes due 2031

Trading Symbol

TMO 31

Security Exchange Name

NYSE

2.375% Notes due 2032

Entity Listings [Line Items]

Title of 12(b) Security

2.375% Notes due 2032

Trading Symbol

TMO 32

Security Exchange Name

NYSE

3.650% Notes due 2034

Entity Listings [Line Items]

Title of 12(b) Security

3.650% Notes due 2034

Trading Symbol

TMO 34

Security Exchange Name

NYSE

3.628% Notes due 2035

Entity Listings [Line Items]

Title of 12(b) Security

3.628% Notes due 2035

Trading Symbol

TMO 35A

Security Exchange Name

NYSE

2.875% Notes due 2037

Entity Listings [Line Items]

Title of 12(b) Security

2.875% Notes due 2037

Trading Symbol

TMO 37

Security Exchange Name

NYSE

1.500% Notes due 2039

Entity Listings [Line Items]

Title of 12(b) Security

1.500% Notes due 2039

Trading Symbol

TMO 39

Security Exchange Name

NYSE

1.875% Notes due 2049

Entity Listings [Line Items]

Title of 12(b) Security

1.875% Notes due 2049

Trading Symbol

TMO 49

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityListingsLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_A1.45SeniorNotesDue2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes175Due2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_FloatingSeniorRateNotesDue2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes0.500Due2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes1.375Due2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes1.95Due2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes0.875Due2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes2375Due2032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes3650Due2034Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes3.628Due2035Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes2.875Due2037Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes1.500Due2039Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=tmo_SeniorNotes1.875Due2049Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: